On March 31, 2025, Williams & Connolly clients Bristol Myers Squibb Company and Celgene Corporation won dismissal of a putative class action antitrust matter where plaintiffs claimed that the companies unlawfully monopolized a market for their Pomalyst product, allegedly by unlawfully asserting patents on the medicine, and by allegedly reaching “reverse payment” settlements with a generic manufacturer. U.S. District Judge Edgardo Ramos of the Southern District of New York held that plaintiffs failed to state a claim under the Sherman Act and analogous state laws.
The Williams & Connolly team representing BMS and Celgene included Benjamin Greenblum, David Kurtzer-Ellenbogen, Stanley Fisher, Aaron Maurer, Andrew Lemens, John McGowan, Alexandra Trobe, and Alex Heldman.
Click here to read Reuters’ coverage of the case and click here to read Law360’s coverage of the case.